{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:49Z","timestamp":1790743789504,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Rituximab is an anti\u2010CD20 monoclonal antibody approved in non\u2010Hodgkin lymphoma (NHL). This study aimed to assess the relationship between antigen mass and nonlinear pharmacokinetics of rituximab in NHL patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a retrospective cohort of 25 NHL patients treated with rituximab, antigen mass was assessed at baseline by measuring metabolic tumour volume (MTV) by positron emission tomography. Rituximab pharmacokinetics was described using a semimechanistic 2\u2010compartment model including a latent target antigen. Rituximab target\u2010mediated elimination was described as irreversible binding between rituximab and it target. Histology (follicular or diffuse large B\u2010cell lymphomas), initial MTV and body weight were tested as covariates on pharmacokinetic parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model allowed a satisfactory description of rituximab serum concentrations. Target\u2010mediated elimination was maximum at the beginning of treatment and became negligible towards the end of follow\u2010up. The second\u2010order elimination of rituximab due to target binding and complex elimination increased with baseline MTV. Central volume of distribution increased with body weight (<jats:italic>P =<\/jats:italic> .022) and baseline MTV (<jats:italic>P =<\/jats:italic> .005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study quantified for the first time the target\u2010mediated elimination of rituximab in NHL patients and confirmed rituximab retention by antigen mass.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13991","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:53:43Z","timestamp":1558486423000},"page":"2002-2010","source":"Crossref","is-referenced-by-count":26,"title":["Nonlinear pharmacokinetics of rituximab in non\u2010Hodgkin lymphomas: A pilot study"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-4545","authenticated-orcid":false,"given":"David","family":"Ternant","sequence":"first","affiliation":[{"name":"EA 7501 GICC Universit\u00e9 de Tours  Tours France"},{"name":"Service de Pharmacologie M\u00e9dicale CHRU de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Monjanel","sequence":"additional","affiliation":[{"name":"H\u00e9matologie et Th\u00e9rapie Cellulaire CHRU de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Venel","sequence":"additional","affiliation":[{"name":"M\u00e9decine Nucl\u00e9aire CHRU de Tours  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Prunier\u2010Aesch","sequence":"additional","affiliation":[{"name":"Chambray Les Tours M\u00e9decine Nucl\u00e9aire Tourangelle  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavie","family":"Arbion","sequence":"additional","affiliation":[{"name":"Service d'Anatomie et Cytologie Pathologiques CHRU de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Colombat","sequence":"additional","affiliation":[{"name":"H\u00e9matologie et Th\u00e9rapie Cellulaire CHRU de Tours  Tours France"},{"name":"ERL CNRS 7001 LNOx Universit\u00e9 de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[{"name":"EA 7501 GICC Universit\u00e9 de Tours  Tours France"},{"name":"Service de Pharmacologie M\u00e9dicale CHRU de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"H\u00e9matologie et Th\u00e9rapie Cellulaire CHRU de Tours  Tours France"},{"name":"ERL CNRS 7001 LNOx Universit\u00e9 de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00714.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3524-9"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3083-x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380949"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000184162.60197.c1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13271"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-744292"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011430506"},{"key":"e_1_2_8_10_1","first-page":"25","article-title":"Influence of FCGR3A\u2010158V\/F genotype and baseline CD20 antigen count on target\u2010mediated elimination of rituximab in patients with chronic lymphocytic leukemia: a study of FILO Group","volume":"2016","author":"Tout M","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13270"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277075"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12098"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175125"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250902992901"},{"key":"e_1_2_8_16_1","first-page":"018","article-title":"Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans","volume":"2018","author":"Ternant D","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12316"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"issue":"8","key":"e_1_2_8_19_1","first-page":"1342","article-title":"Comparison of different methods for delineation of 18F\u2010FDG PET\u2010positive tissue for target volume definition in radiotherapy of patients with non\u2010small cell lung cancer","volume":"46","author":"Nestle U","year":"2005","journal-title":"J Nucl Med"},{"key":"e_1_2_8_20_1","first-page":"42","article-title":"Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non\u2010Hodgkin's lymphoma and exposure\u2010response in CLL","volume":"2014","author":"Gibiansky E","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13882"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0027-4"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-1026-z"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T01:31:33Z","timestamp":1694309493000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/bcp.13991"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13991","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]}}}